2003
DOI: 10.1136/jnnp.74.suppl_2.ii9
|View full text |Cite
|
Sign up to set email alerts
|

Management of Inflammatory Neuropathies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
19
0

Year Published

2010
2010
2024
2024

Publication Types

Select...
5
3
1

Relationship

0
9

Authors

Journals

citations
Cited by 31 publications
(19 citation statements)
references
References 7 publications
0
19
0
Order By: Relevance
“…Although children with CIDP have a favorable response to immunomodulation, the overall prognosis is variable; many patients improve and even recover, but a subset remains with significant neurologic deficits that may lead to death. [4][5][6][7][8][9][10][11] Although childhood CIDP is a distinctive entity, there are clinical variants in which CIDP research criteria cannot be met but which do respond to immune modulating therapy. In the present study, we detected CD59 deficiency in 5 infants from 4 unrelated families of North-African Jewish origin with chronic hemolysis accompanied by sensory-motor, demyelinating, or axonal peripheral polyneuropathy.…”
Section: Introductionmentioning
confidence: 99%
“…Although children with CIDP have a favorable response to immunomodulation, the overall prognosis is variable; many patients improve and even recover, but a subset remains with significant neurologic deficits that may lead to death. [4][5][6][7][8][9][10][11] Although childhood CIDP is a distinctive entity, there are clinical variants in which CIDP research criteria cannot be met but which do respond to immune modulating therapy. In the present study, we detected CD59 deficiency in 5 infants from 4 unrelated families of North-African Jewish origin with chronic hemolysis accompanied by sensory-motor, demyelinating, or axonal peripheral polyneuropathy.…”
Section: Introductionmentioning
confidence: 99%
“…There was a non-significant trend toward a better outcome noted in the group receiving longer treatment of 6 days, and this trend reached significance when only ventilated patients were considered, but the shorter course such as 3 days was proven to be significantly less effective 57,58,59 .…”
Section: High-dose Immunoglobulinmentioning
confidence: 87%
“…Rarely, an LP may be helpful in differential diagnosis from GBS, when EMG is not available. However it should always be kept in mind that the CSF protein levels may be normal during the first week of GBS [14]. Therefore an LP is generally not indicated at the initial presentation of acute ataxia [1].…”
Section: Discussionmentioning
confidence: 99%